Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
P&G: Margin squeeze continues - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

P&G: Margin squeeze continues
Feb 14, 2012

Procter & Gamble Hygiene and Health Care Ltd. has announced its second quarter results for 2011-2012 (2QFY12) (June ending company). The company has reported a 18.7% YoY growth in sales and a 13.8% YoY increase in net profits. Here is our analysis of the results.

Performance summary
  • Sales increased by 18.7% YoY during the 2QFY12 led by double-digit growth in sales of feminine hygiene. During 1HFY12, sales were up by 24.6%.
  • Operating (EBITDA) margins for the company contracted by 140 basis points due to steep rise in raw material costs and wages. For 1HFY12, operating profitability reduced by 290 basis points.
  • Earnings increased by 13.8% backed by 9.6% rise in operating income and 61% jump in other income.
  • The net profits for 1HFY12 have grown at a robust 23% aided by 33% cut in tax outgo.

Rs(m) 2QFY11 2QFY12 Change 1HFY11 1HFY12 Change
Income 2,990 3,548 18.7% 5272.1 6568.7 24.6%
Expenditure 2,431 2,936 20.8% 4351.7 5606.4 28.8%
Operating profit (EBDITA) 559 613 9.6% 920 962 4.6%
EBDITA margin (%) 18.7% 17.3%   17.5% 14.6%  
Other income 79 127 60.9% 165.5 255.1 54.1%
Interest 0 0   0.1 0  
Depreciation 54 66 21.1% 102.2 129.8 27.0%
Profit before tax 584 674 15.4% 984 1,088 10.6%
Extraordinary inc/(exp) - -   - -  
Tax 135 163 20.7% 220.5 147.9 -32.9%
Profit after tax/(loss) 450 512 13.8% 763 940 23.1%
Net profit margin (%) 15.0% 14.4%   14.5% 14.3%  
No. of shares (m)         32  
Diluted earnings per share (Rs)*         52  
Price to earnings ratio (x)*         35.84  
*trailing twelve months

What has driven performance in 2QFY12?
  • Sales of Procter & Gamble Hygiene and Health Care Limited (PGHH) grew by a robust 18.7% YoY during the quarter driven by 24% growth in sales of feminine hygiene products. The excise duty on feminine hygiene products was halved to 5% in the Union Budget 2011-12 that also contributed to the brisk growth. The healthcare category clocked a 7% rise in sales driven by the launch of Vicks Vapocool.

  • The robust topline growth has failed to percolate to the operating level on account of a sharp rise in cost of goods sold. As a proportion of sales, the cost of goods sold increased by 200 basis points during the quarter. The staff costs and advertisement to sales ratios rose by 150 and 30 basis points, respectively. The share of other expenditure dropped to 17.8% from 20.1% in the year-ago quarter. But this measure was insufficient to plug the downfall in operating profit margin that slid by 140 basis points.

  • At 13.8%, growth in net profit bettered the 9.6% rise in operating income on the back of a 61% jump in other income earned during the quarter.

    Cost break-up
    As a % of net sales 2QFY11 2QFY12 Change in basis points
    Total Cost of goods 38.3% 40.3% 199.84
    Staff Cost 3.6% 5.0% 145.48
    Advertising 19.3% 19.6% 30.07
    Other Expenditure 20.1% 17.8% -231.66

What to expect?
PGHH has not launched new products or entered new categories for a long time. Despite lowered excise duty on feminine hygiene products, its profitability has remained under cloud. Its parent has announced expansion plans in the unlisted subsidiary, Procter & Gamble Home Products (PGHP) which is the largest subsidiary present in big categories such as laundry, skincare, haircare and is also the parent company's vehicle for new product launches and innovations. However, PGHH's presence in the under-penetrated feminine hygiene products lends it good growth potential.

At a price of Rs. 1,861, the stock is trading at 20 times our estimated FY14 earnings. However, at current valuations, the stock appears overpriced and we would advise investors to exercise caution.

To Read the Full Story, Subscribe or Sign In

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jun 22, 2018 (Close)


  • Track your investment in P&G HYGIENE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks